AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

NovoCure Limited (NVCR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

21.60

-0.21 (-0.96%)

At close: Feb 20, 2025, 3:59 PM

21.79

0.88%

After-hours: Feb 20, 2025, 06:33 PM EST

undefined% (undefined)

Bid	21.51
Market Cap	2.34B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.39
PE Ratio (ttm)	-15.54
Forward PE	n/a
Analyst	Buy

Ask	22.01
Volume	468,170
Avg. Volume (20D)	1,200,540
Open	21.77
Previous Close	21.81
Day's Range	21.39 - 22.10
52-Week Range	11.70 - 34.13
Beta	undefined

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed c...

[Show more]

Industry Medical - Instruments & Supplies

Sector Healthcare

IPO Date Oct 1, 2015

Employees 1,453

Stock Exchange NASDAQ

Ticker Symbol NVCR

Website https://www.novocure.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for NVCR stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 75.93% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

NovoCure Limited is scheduled to release its earnings on Feb 27, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+11.14%

NovoCure shares are trading higher after Piper San... Unlock content with Pro Subscription

2 months ago

+48.95%

NocoCure shares are trading higher after the company announced its Phase 3 PANOVA-Trial met its primary endpoint and demonstrated a statistically significant improvement in its median overall survival rate.

News

13 hours ago · zacks.com

NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago · businesswire.com

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

BAAR, Switzerland--(BUSINESS WIRE)--Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland.

1 month ago · businesswire.com

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update.

1 month ago · businesswire.com

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference.

2 months ago · fool.com

Why NovoCure Stock Was Winning Big This Week

Cancer-targeting biotech NovoCure (NVCR -9.00%) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum...

2 months ago · fool.com

Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?

The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances...

2 months ago · seekingalpha.com

NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer

NovoCure's TTFields therapy, combined with standard chemotherapy, significantly improves overall survival in advanced pancreatic cancer, showing a 33% improvement in two-year survival rates. Despite p...

2 months ago · zacks.com

NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals

Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.

2 months ago · seekingalpha.com

Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields

Positive results achieved from phase 3 PANOVA-3 study using TTFields + Gemcitabine + Nab-paclitaxel to treat unresectable, locally advanced 1st-line pancreatic cancer patients. Multiple regulatory sub...

2 months ago · benzinga.com

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients

On Monday, NovoCure Ltd NVCR and Zai Lab Limited ZLAB revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxe...

Load More News